Michael J Alberti

Publications (4)13.62 Total impact

• Article: The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.

  Mui Cheung, Philip A Harris, Jennifer G Badiang, Gregory E Peckham, Stanley D Chamberlain, Michael J Alberti, David K Jung, Stephanie S Harris, Neal H Bramson, Andrea H Epperly, Stephen A Stimpson, Michael R Peel
  [show abstract] [hide abstract]
  ABSTRACT: A series of pyrazolo[1,5-a]pyridine derivatives was designed and synthesized as novel potent p38 kinase inhibitors. Our approaches towards improving in vitro metabolism and in vivo pharmacokinetic properties of the series are described.
  Bioorganic & medicinal chemistry letters 10/2008; 18(20):5428-30. · 2.65 Impact Factor
• Article: Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors.

  Kirk L Stevens, David K Jung, Michael J Alberti, Jennifer G Badiang, Gregory E Peckham, Jim M Veal, Mui Cheung, Philip A Harris, Stanley D Chamberlain, Michael R Peel
  [show abstract] [hide abstract]
  ABSTRACT: [reaction: see text] A convergent synthesis of substituted pyrazolo[1,5-a]pyridines has been achieved either via a regioselective [3 + 2] cycloaddition of N-aminopyridines with alkynes or by thermal cyclization of disubstituted azirines. Subsequent palladium-catalyzed introduction of pyridines or de novo synthesis of pyrimidines affords inhibitors of p38 kinase.
  Organic Letters 11/2005; 7(21):4753-6. · 5.86 Impact Factor
• Article: Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.

  Michael J Alberti, Elizabeth P Auten, Karen E Lackey, Octerloney B McDonald, Edgar R Wood, Frank Preugschat, Geoffrey J Cutler, Laurie Kane-Carson, Wei Liu, David K Jung
  [show abstract] [hide abstract]
  ABSTRACT: The discovery, synthesis, potential binding mode, and in vitro kinase profile of several pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines as potent kinase inhibitors are discussed.
  Bioorganic & Medicinal Chemistry Letters 09/2005; 15(16):3778-81. · 2.55 Impact Factor
• Article: (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors.

  Mark J Bamford, Michael J Alberti, Nicholas Bailey, Susannah Davies, David K Dean, Alessandra Gaiba, Stephen Garland, John D Harling, David K Jung, Terence A Panchal, Christopher A Parr, Jon G Steadman, Andrew K Takle, James T Townsend, David M Wilson, Jason Witherington
  [show abstract] [hide abstract]
  ABSTRACT: A novel series of imidazo[4,5-c]pyridines bearing a 1,2,5-oxadiazol-3-ylamine functionality has been developed. These are potent inhibitors of mitogen and stress-activated protein kinase-1.
  Bioorganic & Medicinal Chemistry Letters 08/2005; 15(14):3402-6. · 2.55 Impact Factor